Unregulated peptide use on TikTok: what the science says

What did @charitykface actually say?

In this video, the creator walks through an evening peptide routine that includes DSIP, Tessa Morelin, KPV, GHK-Cu, BPC-157, TB-500, and NAD, while also reflecting on her weight loss journey. The main argument she lands on is about AOD-9604: "if you aren't at your goal, don't be discouraged thinking that the peptide doesn't work." Her theory is that fat-targeting peptides like AOD-9604 show more visible results when you already have less body fat. She also applies this logic to Pilates, arguing the physical benefits are more apparent when you weigh less. She's careful to note this is personal experience, adding she's only "46% sure" AOD-9604 would work better for her now. She does not claim any of these peptides treat or cure a disease.

Does the science back this up?

Partially, but not in the way she's framing it. The idea that body composition affects how you perceive a treatment's results is not wrong, but calling AOD-9604 a reliable fat-loss tool at any stage overstates the evidence considerably.

AOD-9604 is a synthetic fragment of human growth hormone (hGH176-191). Early animal studies, including work by Heffernan et al. (2001, Endocrinology), showed lipolytic effects in obese mice. But human trials have been far less convincing. A Phase 2b trial by Ng et al. (2013, Obesity) found no statistically significant difference in weight loss versus placebo in overweight adults. The FDA has not approved AOD-9604 for any indication. It is not currently classified as a Generally Recognized as Safe (GRAS) ingredient for human use in this context.

Her broader point, that visible body-recomposition results are easier to notice at lower body fat percentages, does have physiological logic. Muscle definition becomes visible at lower subcutaneous fat levels, which is established in exercise science literature. But this is about perception of results, not about whether a peptide is pharmacologically active at a given body weight.

What did they get wrong (or right)?

She got the perception argument roughly right, and wrong on the mechanism. Attributing poor AOD-9604 results to being "too heavy" implies the peptide works better at lower body fat, but there is no peer-reviewed human evidence to support that dose-response relationship. It is equally plausible that AOD-9604 simply did not produce meaningful fat loss effects, full stop, which aligns with the clinical trial data.

She also makes a stack worth flagging. Running DSIP, NAD, BPC-157, TB-500, KPV, GHK-Cu, and Tessa Morelin simultaneously is a significant pharmacological load. DSIP (delta sleep-inducing peptide) has limited human safety data. TB-500 (thymosin beta-4 fragment) is explicitly on the World Anti-Doping Agency prohibited list. None of these combinations have been studied together in controlled human trials. Her disclaimer, "don't do what I do," is doing a lot of heavy lifting here.

Credit where it's due: she is transparent about uncertainty, uses hedged language consistently, and does not tell her audience to buy or take specific doses. That is more responsible than most peptide content on this platform.

What should you actually know?

The peptides in this video sit in a murky regulatory space. Most are not FDA-approved for human use, and several, including BPC-157 and TB-500, have been the subject of FDA guidance restricting their compounding. The FDA issued a statement in 2023 removing BPC-157 from the list of bulk drug substances that can be used in compounding.

The "things work better when you're smaller" framing is worth unpacking critically. For exercise modalities like Pilates, the evidence supports the idea that lower body mass reduces mechanical load and allows for better proprioceptive feedback (Keogh and Briffa, 2015, Journal of Aging and Physical Activity). For peptides, no such weight-stratified efficacy data exists in peer-reviewed human literature. Viewers should not interpret her personal n=1 experience as a pharmacological principle.

• AOD-9604 failed to beat placebo in its most rigorous human trial.
• TB-500 is a prohibited substance under WADA rules.
• Stacking multiple peptides without clinical oversight carries unstudied interaction risks.
• Regulatory status for most peptides discussed is non-approved or actively restricted.
• Consult a licensed clinician before starting any peptide protocol, not a TikTok comment section.